The CSL Limited (ASX: CSL) share price has underperformed the broader market in March despite no negative news from the company.
In fact, only one price-sensitive release from the biotechnology giant hit the market over the last 31 days. Still, the CSL share price has managed to record a gain for the month.
At the time of writing, it’s trading at $270, 3.8% higher than it was at the end of February.
For context, the S&P/ASX 200 Index (ASX: XJO) has risen 6.8% over the same period.
So, what’s been driving the ASX 200 staple’s stock lately? Let’s take a look.
What’s been driving the CSL share price in March?
There was only one price-sensitive update released by CSL this month – and it managed to send its share price just 0.3% higher.
The news was in regards to the company’s US$12.3 billion acquisition of Swiss-listed Vifor Pharma.
News of the acquisition, which spurred a US$4.5 billion capital raise, first broke in mid-December.
The latest update on the transaction dropped on 4 March. Then, the company announced 74% of Vifor Pharma’s shares were tendered under its public tender offer.
In response to the acceptance rate, the company waived its previous goal of 80% and declared the offer a success.
The next step the company was to take – a tender period for subsequent acceptance of the offer – was to begin on 9 March and continue until 22 March.
Additionally, CSL stated regulatory approvals were going well and it was confident the acquisition would be finished around the middle of this year.
Unfortunately, the CSL share price tumbled 3.3% the following trading day (7 March). However, the slump wasn’t totally unexpected.
That’s because CSL traded ex-dividend on 7 March. That means new investors had missed their window to get their hands on CSL’s US$1.04 per share unfranked interim dividend.
Generally, shares fall on their ex-dividend dates because the value of their upcoming dividend is no longer attached to their stock.
Finally, the CSL share price took off on 8 March, gaining 2.8% amid news the company’s new influenza vaccine had gained regulatory approval to be used in children above the age of two.
However, the company’s decent March gains haven’t been enough to boost the company’s stock back into the long-term green.
The CSL share price is still almost 9% lower than it was at the start of 2022.
The post How did the CSL share price perform in March? appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- Why is the CSL share price climbing on Wednesday?
- What’s the outlook for the CSL share price in April?
- Expert reveals 3 ASX shares to watch following tonight’s federal budget
- Why the CSL (ASX:CSL) share price will ‘find its mojo again’: expert
- 3 ASX shares I own myself that will rise again soon: expert
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/mcnZJf2
Leave a Reply